SEATTLE--(BUSINESS WIRE)--AltPep Corporation, a privately held biotechnology company developing early disease-modifying treatments and detection tools for amyloid diseases, today announced that accomplished executive Nancy Hill has assumed the newly created role of Chief Product Officer. In this role, Nancy is responsible for product development and commercialization of AltPep’s pipeline.
“We are thrilled to welcome Nancy to AltPep as we focus on advancing our products through development,” said Valerie Daggett, Ph.D., Founder and CEO of AltPep. “Nancy’s unique experience building and scaling innovation-driven healthcare companies will be instrumental to ensuring our products are available to address the significant unmet needs for diagnosis and treatment of amyloid diseases.”
Nancy Hill joins AltPep from Adaptive Biotechnologies where she most recently served as an officer and Executive Vice President of Operations and Program Management. Nancy was part of the executive team that successfully grew the company from early stage through IPO and beyond. Prior to Adaptive, Nancy led Sales and Marketing and was a member of the executive team at Spiration, Inc., a venture-backed medical device company which was acquired by Olympus. She has also had senior leadership positions in Berlex Laboratories, Immunex Corporation and Amgen. Nancy earned an MBA from the Kellogg School of Management at Northwestern University (Kellogg) and a BA in Business Administration from the University of Washington. She is currently President of the Seattle Chapter of the Healthcare Businesswomen’s Association (HBA), and a member of Kellogg’s Alumni Council and Hawryluk Scholars Mentorship Council. Nancy is also a recipient of HBA’s Leadership Excellence and Dedication Award.
About AltPep Corporation
AltPep is developing early disease-modifying treatments and detection tools for amyloid diseases by targeting one of the earliest molecular triggers – toxic soluble oligomers. These oligomers are associated with many diseases, including neurodegenerative diseases and type 2 diabetes. Decades of scientific research by the Daggett Research Group culminated in the discovery of a novel protein structure, alpha-sheet, the foundation of AltPep’s innovative approach.
Our lead program aims to identify Alzheimer’s disease long before symptoms occur and then neutralize the toxic soluble oligomers associated with the disease. For more information, please visit www.altpep.com or follow us on LinkedIn.